Article Versions Notes

Hong J, Johnson WT, Kartan S, Gonsalves AS, Fenkel JM, Gong JZ, Porcu P. Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD). Current Oncology. 2021; 28(6):5067-5072. https://doi.org/10.3390/curroncol28060426

Hong, Jennifer, William T. Johnson, Saritha Kartan, Anitha S. Gonsalves, Jonathan M. Fenkel, Jerald Z. Gong, and Pierluigi Porcu. 2021. "Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD)" Current Oncology 28, no. 6: 5067-5072. https://doi.org/10.3390/curroncol28060426

Hong, J., Johnson, W. T., Kartan, S., Gonsalves, A. S., Fenkel, J. M., Gong, J. Z., & Porcu, P. (2021). Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD). Current Oncology, 28(6), 5067-5072. https://doi.org/10.3390/curroncol28060426